Related Experiment Videos
Preclinical targeted alpha therapy for subcutaneous melanoma
1Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Gray St Kogarah, Australia. b.allen@unsw.edu.au
Melanoma Research
|May 3, 2001
Summary
Targeted alpha therapy (TAT) using bismuth-213 immunoconjugates effectively controls melanoma growth in mice. Local injections achieved complete tumor regression with no side effects, supporting clinical trials.
Area of Science:
- Oncology
- Nuclear Medicine
- Immunotherapy
Background:
- Malignant melanoma remains a significant health concern, necessitating novel therapeutic strategies.
- Targeted alpha therapy (TAT) offers a promising approach for localized cancer treatment due to the high energy and short range of alpha particles.
- Alpha-emitting immunoconjugates (AICs) combine the targeting specificity of monoclonal antibodies with the cytotoxic potential of alpha-emitting radioisotopes.
Purpose of the Study:
- To evaluate the efficacy and safety of an alpha-emitting immunoconjugate (AIC) utilizing bismuth-213 for the treatment of subcutaneous melanoma in a preclinical mouse model.
- To determine optimal activity tolerances for both intraperitoneal and intralesional administration of the AIC.
- To assess the therapeutic potential of local versus systemic TAT in controlling melanoma tumor growth.
Main Methods:
- Preparation of an AIC by conjugating bismuth-213 to a melanoma-specific monoclonal antibody.
- Administration of the AIC via intraperitoneal and intralesional injections in a nude mouse model bearing subcutaneous melanoma xenografts.
- Evaluation of tumor growth inhibition, regression, and survival following different activity levels and administration routes.
- Assessment of potential side effects associated with the treatment.
Main Results:
- Activity tolerances were established at 8 mCi/kg for intraperitoneal and 10 mCi/kg for intralesional injections.
- Local TAT via intralesional injections demonstrated significant inhibition of tumorigenesis and tumor regression, with complete regression of melanomas up to 300 mm3 observed at 100 microCi without side effects.
- Systemic TAT showed limited efficacy, resulting in tumor growth delay and partial inhibition.
- Isolated cancer cells and preangiogenic cell clusters were effectively eliminated by local TAT.
Conclusions:
- Local targeted alpha therapy with bismuth-213 immunoconjugates is highly effective in controlling and regressing subcutaneous melanoma in a preclinical setting.
- Intralesional administration of AICs demonstrates superior efficacy and a favorable safety profile compared to systemic administration.
- These findings provide a strong rationale for advancing targeted alpha therapy with AICs into clinical trials for recurrent subcutaneous melanoma.